Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age
The American Journal of Cardiology Apr 18, 2019
Malik AH, et al. - Researchers compared direct-acting oral anticoagulants (DOACs) to warfarin, in terms of efficacy and safety, in older patients with nonvalvular atrial fibrillation (AF). For this purpose, they analyzed five substudies of randomized controlled trials, with 28,135 older patients. These randomized controlled trials were identified from PubMed, Embase, and Cochrane Central databases and involved AF patients who were >75 years old and were treated with DOACs or warfarin. Findings revealed a greater safety as well as efficacy of DOACs vs warfarin for the treatment of nonvalvular AF in older patients. In these patients, the best combination of efficacy and safety was seemed to be offered by apixaban.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries